Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Immunosuppressive drugs in HIV disease.

Argyropoulos C, Mouzaki A.

Curr Top Med Chem. 2006;6(16):1769-89. Review.

PMID:
17017956
2.

Evaluation of HIV-1 and CD4+ T cell dynamic parameters in patients treated with genotypic resistance testing-guided HAART.

Cappuccio A, Castiglione F, Piccoli B, Tozzi V.

Curr HIV Res. 2008 Jun;6(4):363-9.

PMID:
18691034
3.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

4.
5.

Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.

Terzieva V, Popova D, Kicheva M, Todorova Y, Markova R, Martinova F, Elenkov I, Yankova M.

Int Immunopharmacol. 2009 Jul;9(7-8):831-6. doi: 10.1016/j.intimp.2009.03.009. Epub 2009 Mar 18.

PMID:
19303058
6.

Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation.

Ciuffreda D, Pantaleo G, Pascual M.

Transpl Int. 2007 Aug;20(8):649-58. Epub 2007 Apr 8. Review.

7.
8.

Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.

Zhang ZN, Shang H, Jiang YJ, Liu J, Dai D, Diao YY, Geng WQ, Jin X, Wang YN.

Chin Med J (Engl). 2006 Dec 5;119(23):1966-71.

PMID:
17199940
9.

Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy.

Montoya CJ, Rugeles MT, Landay AL.

Expert Rev Anti Infect Ther. 2006 Oct;4(5):767-80. Review.

PMID:
17140354
10.

New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Ravot E, Lisziewicz J, Lori F.

Drugs. 1999 Dec;58(6):953-63. Review.

PMID:
10651384
11.

HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.

Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, Kallás EG, de Moraes-Pinto MI.

Cytometry B Clin Cytom. 2007 Jan 15;72(1):14-21.

12.

Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138.

Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, Wang H, Sevin A, Tebas P, Sieg SF, Medvik K, Margolis DM, Pollard R, Ertl HC, Valdez H.

J Infect Dis. 2006 Dec 15;194(12):1677-85. Epub 2006 Nov 2.

13.

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.

Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, Echeverry M, Arango AE, Prada MC, Alarcon Hdel P, Rojas M.

Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8.

14.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
15.

Human immunodeficiency virus and liver transplantation: our point of view.

Di Benedetto F, Di Sandro S, De Ruvo N, Berretta M, Montalti R, Guerrini GP, Ballarin R, De Blasiis MG, Spaggiari M, Smerieri N, Iemmolo RM, Guaraldi G, Gerunda GE.

Transplant Proc. 2008 Jul-Aug;40(6):1965-71. doi: 10.1016/j.transproceed.2008.05.067.

PMID:
18675102
16.

Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.

Kovarik JM, Burtin P.

Expert Opin Emerg Drugs. 2003 May;8(1):47-62. Review.

PMID:
14610911
17.

Nanochemistry-based immunotherapy for HIV-1.

Lori F, Calarota SA, Lisziewicz J.

Curr Med Chem. 2007;14(18):1911-9. Review.

PMID:
17691933
18.

Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy.

Chagan-Yasutan H, Saitoh H, Ashino Y, Arikawa T, Hirashima M, Li S, Usuzawa M, Oguma S, O Telan EF, Obi CL, Hattori T.

Tohoku J Exp Med. 2009 Aug;218(4):285-92.

19.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
20.

Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial.

Montoya CJ, Jaimes F, Higuita EA, Convers-Páez S, Estrada S, Gutierrez F, Amariles P, Giraldo N, Peñaloza C, Rugeles MT.

Trials. 2009 Jun 18;10:41. doi: 10.1186/1745-6215-10-41.

Items per page

Supplemental Content

Write to the Help Desk